Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
Microbot Medical (NASDAQ: MBOT) announced its participation in the first-ever Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting in Strasbourg, France from July 16-20, 2025. The session, titled "Endovascular Robotics; the next frontier for robotic surgery," will take place on July 19th at 1:30am CEST.
The panel will be moderated by Dr. Adnan Siddiqui from the University of Buffalo and Dr. Ryan Madder from Corewell Health. CEO Harel Gadot will present an overview of the endovascular robotic market and discuss the company's LIBERTY® Endovascular Robotic System, which is currently awaiting FDA 510(k) clearance expected this quarter.
Microbot Medical (NASDAQ: MBOT) ha annunciato la sua partecipazione alla prima sessione dedicata alla Robotica Endovascolare, che si terrà durante il congresso annuale della Society of Robotic Surgery (SRS) a Strasburgo, Francia, dal 16 al 20 luglio 2025. La sessione, intitolata "Robotica Endovascolare: la nuova frontiera della chirurgia robotica", avrà luogo il 19 luglio alle 1:30 CEST.
Il panel sarà moderato dal Dott. Adnan Siddiqui dell'Università di Buffalo e dal Dott. Ryan Madder di Corewell Health. Il CEO Harel Gadot presenterà una panoramica del mercato della robotica endovascolare e parlerà del LIBERTY® Endovascular Robotic System dell’azienda, attualmente in attesa dell’approvazione FDA 510(k), prevista per questo trimestre.
Microbot Medical (NASDAQ: MBOT) anunció su participación en la primera sesión dedicada a la Robótica Endovascular en la reunión anual de la Society of Robotic Surgery (SRS) en Estrasburgo, Francia, del 16 al 20 de julio de 2025. La sesión, titulada "Robótica Endovascular; la próxima frontera en cirugía robótica", se llevará a cabo el 19 de julio a la 1:30 am CEST.
El panel será moderado por el Dr. Adnan Siddiqui de la Universidad de Buffalo y el Dr. Ryan Madder de Corewell Health. El CEO Harel Gadot presentará una visión general del mercado de la robótica endovascular y hablará sobre el LIBERTY® Endovascular Robotic System de la compañía, que actualmente está a la espera de la aprobación FDA 510(k), esperada para este trimestre.
Microbot Medical (NASDAQ: MBOT)은 2025년 7월 16일부터 20일까지 프랑스 스트라스부르에서 열리는 Society of Robotic Surgery(SRS) 연례회의에서 최초로 개최되는 혈관내 로봇 수술 세션에 참여한다고 발표했습니다. "혈관내 로봇 수술; 로봇 수술의 다음 경계"라는 제목의 세션은 7월 19일 오전 1시 30분(CEST)에 진행됩니다.
패널은 버팔로 대학교의 Adnan Siddiqui 박사와 Corewell Health의 Ryan Madder 박사가 진행하며, CEO Harel Gadot는 혈관내 로봇 시장 개요를 소개하고 현재 이번 분기 FDA 510(k) 승인 대기 중인 회사의 LIBERTY® Endovascular Robotic System에 대해 설명할 예정입니다.
Microbot Medical (NASDAQ : MBOT) a annoncé sa participation à la toute première session sur la robotique endovasculaire lors de la réunion annuelle de la Society of Robotic Surgery (SRS) à Strasbourg, France, du 16 au 20 juillet 2025. La session, intitulée « Robotique endovasculaire : la prochaine frontière de la chirurgie robotique », se tiendra le 19 juillet à 1h30 CEST.
Le panel sera animé par le Dr Adnan Siddiqui de l'Université de Buffalo et le Dr Ryan Madder de Corewell Health. Le PDG Harel Gadot présentera un aperçu du marché de la robotique endovasculaire et discutera du LIBERTY® Endovascular Robotic System de la société, actuellement en attente de l'autorisation FDA 510(k) prévue pour ce trimestre.
Microbot Medical (NASDAQ: MBOT) gab bekannt, dass es an der ersten Endovaskulären Robotik-Sitzung auf der Jahrestagung der Society of Robotic Surgery (SRS) in Straßburg, Frankreich, vom 16. bis 20. Juli 2025 teilnimmt. Die Sitzung mit dem Titel „Endovaskuläre Robotik: die nächste Grenze der robotergestützten Chirurgie“ findet am 19. Juli um 1:30 Uhr CEST statt.
Das Panel wird von Dr. Adnan Siddiqui von der University of Buffalo und Dr. Ryan Madder von Corewell Health moderiert. CEO Harel Gadot wird einen Überblick über den Markt für endovaskuläre Robotik geben und das LIBERTY® Endovascular Robotic System des Unternehmens vorstellen, das derzeit auf die FDA 510(k)-Zulassung wartet, die für dieses Quartal erwartet wird.
- Company is strengthening sales and marketing infrastructure ahead of LIBERTY launch in the US
- FDA 510(k) decision expected in the current quarter
- Platform opportunity to educate Interventional Radiologists about LIBERTY system
- LIBERTY is still an investigational device pending FDA clearance
- Product not yet available for sale in the US
Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the Specialty
HINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, being held from July 16-20, in Strasbourg, France. The Company applauds the SRS for recognizing the growing need to spotlight this field, which Microbot believes is being driven by rapid innovation and rising market demand.
The panel session, titled: Endovascular Robotics; the next frontier for robotic surgery, will take place at 1:30am CEST on Saturday July 19th and will be moderated by Dr. Adnan Siddiqui, a University of Buffalo Distinguished Professor and Vice Chairman in the Department of Neurosurgery (UBNS) at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences, and Dr. Ryan Madder, Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health™ in Grand Rapids, Michigan.
Harel Gadot, the Company’s Chairman, CEO and President, will present an overview of the endovascular robotic market. Mr. Gadot will be joined by representatives from other medical robotics companies to discuss emerging technologies in the peripheral vascular, neurovascular and cardiovascular spaces. The SRS meeting provides the Company with a timely platform to introduce and educate Interventional Radiologists (IR) and the broader medical community on the LIBERTY system.
The SRS is founded on the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery. SRS provides possibilities in terms of multi-centric studies, database collection, fellowship training and funding support. The organization seeks participation from residents and fellows and young faculty in the hope that they can assist them as they embrace robotics. The society is global with each continent having its own board and input into SRS activities.
The Company is strengthening its sales and marketing infrastructure as part of the LIBERTY launch plans in the United States, while awaiting the anticipated U.S. Food and Drug Administration’s (FDA) 510(k) decision during the current quarter.
LIBERTY is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
IR@microbotmedical.com
FAQ
When will Microbot Medical (MBOT) present at the Society of Robotic Surgery 2025 meeting?
What is the current status of Microbot Medical's LIBERTY Endovascular Robotic System?
Who will moderate MBOT's endovascular robotics session at SRS 2025?
What is Microbot Medical's strategy for the LIBERTY system launch?
